• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Breakthrough cytomegalovirus pneumonia in hematopoietic stem cell transplant recipient on letermovir prophylaxis.

作者信息

Knoll Bettina M, Seiter Karen, Phillips Adrienne, Soave Rosemary

机构信息

Department of Medicine, Division of Infectious Diseases, New York Medical College, Valhalla, USA.

Department of Medicine, Division of Hematology, New York Medical College, Valhalla, USA.

出版信息

Bone Marrow Transplant. 2019 Jun;54(6):911-912. doi: 10.1038/s41409-018-0389-9. Epub 2018 Nov 6.

DOI:10.1038/s41409-018-0389-9
PMID:30401966
Abstract
摘要

相似文献

1
Breakthrough cytomegalovirus pneumonia in hematopoietic stem cell transplant recipient on letermovir prophylaxis.接受来特莫韦预防治疗的造血干细胞移植受者发生突破性巨细胞病毒肺炎。
Bone Marrow Transplant. 2019 Jun;54(6):911-912. doi: 10.1038/s41409-018-0389-9. Epub 2018 Nov 6.
2
Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.造血干细胞移植受者在二次莱曲莫韦预防治疗期间出现耐药巨细胞病毒的快速突破。
BMC Infect Dis. 2019 May 8;19(1):388. doi: 10.1186/s12879-019-4016-1.
3
Letermovir for prophylaxis of cytomegalovirus manifestations in adult allogeneic hematopoietic stem cell transplant recipients.来特莫韦用于预防成人异基因造血干细胞移植受者的巨细胞病毒表现。
Future Microbiol. 2019 Feb;14:175-184. doi: 10.2217/fmb-2018-0250. Epub 2019 Jan 15.
4
Letermovir for prophylaxis of cytomegalovirus in allogeneic hematopoietic stem cell recipients.来特莫韦用于异基因造血干细胞移植受者预防巨细胞病毒感染
Drugs Today (Barc). 2018 Jun;54(6):361-368. doi: 10.1358/dot.2018.54.6.2833982.
5
Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation.来特莫韦预防造血干细胞移植后青少年患者巨细胞病毒感染。
J Pediatric Infect Dis Soc. 2022 Jul 21;11(7):337-340. doi: 10.1093/jpids/piac017.
6
[Management of cytomegalovirus infection after hematopoietic stem cell transplantation].[造血干细胞移植后巨细胞病毒感染的管理]
Rinsho Ketsueki. 2019;60(9):1337-1340. doi: 10.11406/rinketsu.60.1337.
7
Letermovir successfully used for secondary prophylaxis in a heart transplant recipient with ganciclovir-resistant cytomegalovirus syndrome (UL97 mutation).来特莫韦成功用于一名患有耐更昔洛韦巨细胞病毒综合征（UL97突变）的心脏移植受者的二级预防。
Transpl Infect Dis. 2018 Oct;20(5):e12965. doi: 10.1111/tid.12965. Epub 2018 Jul 20.
8
Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation.来特莫韦预防造血干细胞移植后巨细胞病毒感染。
N Engl J Med. 2017 Dec 21;377(25):2433-2444. doi: 10.1056/NEJMoa1706640. Epub 2017 Dec 6.
9
Eosinophilia during letermovir treatment after allogeneic hematopoietic stem cell transplantation.异基因造血干细胞移植后使用来特莫韦治疗期间的嗜酸性粒细胞增多症。
Ann Hematol. 2020 Oct;99(10):2453-2454. doi: 10.1007/s00277-020-04226-9. Epub 2020 Aug 21.
10
Letermovir for cytomegalovirus primary prophylaxis in a multiple abdominal/small bowel transplant recipient.来特莫韦用于一名多次接受腹部/小肠移植受者的巨细胞病毒原发性预防。
Clin Transplant. 2022 May;36(5):e14624. doi: 10.1111/ctr.14624. Epub 2022 Mar 4.

引用本文的文献

1
Hematopoietic stem cell donor vaccination with cytomegalovirus triplex augments frequencies of functional and durable cytomegalovirus-specific T cells in the recipient: A novel strategy to limit antiviral prophylaxis.三价巨细胞病毒疫苗增强供者造血干细胞移植受者中功能性和持久性巨细胞病毒特异性 T 细胞的频率：限制抗病毒预防的新策略。
Am J Hematol. 2023 Apr;98(4):588-597. doi: 10.1002/ajh.26824. Epub 2023 Jan 11.
2
Emergence of Letermovir-resistant HCMV UL56 mutant during rescue treatment in a liver transplant recipient with ganciclovir-resistant infection HCMV: a case report.肝移植受者因更昔洛韦耐药感染 HCMV 而接受挽救治疗时出现莱默ovir 耐药的 HCMV UL56 突变：一例报告。
BMC Infect Dis. 2021 Sep 23;21(1):994. doi: 10.1186/s12879-021-06694-4.
3
Antiviral Drugs Against Herpesviruses.抗疱疹病毒药物。
Adv Exp Med Biol. 2021;1322:1-30. doi: 10.1007/978-981-16-0267-2_1.
4
Make Sure You Have a Safety Net: Updates in the Prevention and Management of Infectious Complications in Stem Cell Transplant Recipients.确保你有一个安全保障：干细胞移植受者感染性并发症预防与管理的最新进展
J Clin Med. 2020 Mar 21;9(3):865. doi: 10.3390/jcm9030865.
5
Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation.巨细胞病毒再激活对造血干细胞移植中非复发死亡率的异质性影响。
Blood Adv. 2020 Mar 24;4(6):1051-1061. doi: 10.1182/bloodadvances.2019000814.
6
Poxvirus Vectored Cytomegalovirus Vaccine to Prevent Cytomegalovirus Viremia in Transplant Recipients: A Phase 2, Randomized Clinical Trial.痘病毒载体巨细胞病毒疫苗预防移植受者巨细胞病毒血症：一项 2 期、随机临床试验。
Ann Intern Med. 2020 Mar 3;172(5):306-316. doi: 10.7326/M19-2511. Epub 2020 Feb 11.
7
Moving Past Ganciclovir and Foscarnet: Advances in CMV Therapy.从更昔洛韦和膦甲酸钠转移：CMV 治疗的进展。
Curr Hematol Malig Rep. 2020 Apr;15(2):90-102. doi: 10.1007/s11899-020-00557-6.
8
Letermovir Resistance Analysis in a Clinical Trial of Cytomegalovirus Prophylaxis for Hematopoietic Stem Cell Transplant Recipients.造血干细胞移植受者巨细胞病毒预防的临床试验中的来特莫韦耐药分析。
J Infect Dis. 2020 Mar 16;221(7):1117-1126. doi: 10.1093/infdis/jiz577.
9
Emergence and Persistence of Letermovir-Resistant Cytomegalovirus in a Patient With Primary Immunodeficiency.一名原发性免疫缺陷患者中耐来特莫韦巨细胞病毒的出现与持续存在
Open Forum Infect Dis. 2019 Aug 23;6(9):ofz375. doi: 10.1093/ofid/ofz375. eCollection 2019 Sep.
10
Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review.来特莫韦预防移植受者巨细胞病毒感染和疾病：一项循证综述
Infect Drug Resist. 2019 Jun 4;12:1481-1491. doi: 10.2147/IDR.S180908. eCollection 2019.